Clinical Trial TitleThe Alzheimer's disease genetics initiative: The multiplex family study
Clinical Trial Protocol Description:
The goal of this study is to find genetic factors that determine whether a person is at greater risk of getting Alzheimer's disease after the age of 60.
The study, which is being conducted by the Rush Alzheimer's Disease Center (one of the 30 sites around the country), is sponsored and funded by the National Institute on Aging.
Approximately 1,000 families from across the country will participate. These families will be a national resource for people working to understand how genes play a role in the development of Alzheimer's disease, aging and related disorders.
Eligible family members will undergo an initial collection of data about the family history of memory loss along with individual health and demographic data. Testing of memory functions will be conducted. A sample of blood for genetic analysis will be collected. Results of all genetic tests are for research only and will not be released to individuals or families. Genetic information will not be shared with insurance companies or placed in medical records. Follow-up telephone or in-person visits may be done to update the status of family members.
There will be no cost to people who join the study. All visit procedures will be covered by the research study.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are part of a family where two first-degree individuals have had Alzheimer's disease and one first-degree relative is over the age of 60 and has no memory concerns.
- Speak English or Spanish.
- Are willing to donate a blood sample for genetic analysis.
This is a partial list of eligibility requirements.